TY - JOUR A1 - Schütze, Friedrich A1 - Röhring, Florian A1 - Vorlová, Sandra A1 - Gätzner, Sabine A1 - Kuhn, Anja A1 - Ergün, Süleyman A1 - Henke, Erik T1 - Inhibition of lysyl oxidases improves drug diffusion and increases efficacy of cytotoxic treatment in 3D tumor models JF - Scientific Reports N2 - Tumors are characterized by a rigid, highly cross-linked extracellular matrix (ECM), which impedes homogeneous drug distribution and potentially protects malignant cells from exposure to therapeutics. Lysyl oxidases are major contributors to tissue stiffness and the elevated expression of these enzymes observed in most cancers might influence drug distribution and efficacy. We examined the effect of lysyl oxidases on drug distribution and efficacy in 3D in vitro assay systems. In our experiments elevated lysyl oxidase activity was responsible for reduced drug diffusion under hypoxic conditions and consequently impaired cytotoxicity of various chemotherapeutics. This effect was only observed in 3D settings but not in 2D-cell culture, confirming that lysyl oxidases affect drug efficacy by modification of the ECM and do not confer a direct desensitizing effect. Both drug diffusion and efficacy were strongly enhanced by inhibition of lysyl oxidases. The results from the in vitro experiments correlated with tumor drug distribution in vivo, and predicted response to therapeutics in murine tumor models. Our results demonstrate that lysyl oxidase activity modulates the physical barrier function of ECM for small molecule drugs influencing their therapeutic efficacy. Targeting this process has the potential to significantly enhance therapeutic efficacy in the treatment of malignant diseases. KW - human osteosarcoma xenografts KW - factor binding profiles KW - open-access database KW - vascular normalization KW - solid tumors KW - transcapillary pressure gradient KW - hypoxia inducible factor 1 KW - breast cancer cells KW - beta-aminopropionitrile KW - pancreatic cancer Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-145109 VL - 5 IS - 17576 ER - TY - JOUR A1 - Rosa, Annabelle A1 - Butt, Elke A1 - Hopper, Christopher P. A1 - Loroch, Stefan A1 - Bender, Markus A1 - Schulze, Harald A1 - Sickmann, Albert A1 - Vorlova, Sandra A1 - Seizer, Peter A1 - Heinzmann, David A1 - Zernecke, Alma T1 - Cyclophilin a is not acetylated at lysine-82 and lysine-125 in resting and stimulated platelets JF - International Journal of Molecular Sciences N2 - Cyclophilin A (CyPA) is widely expressed by all prokaryotic and eukaryotic cells. Upon activation, CyPA can be released into the extracellular space to engage in a variety of functions, such as interaction with the CD147 receptor, that contribute to the pathogenesis of cardiovascular diseases. CyPA was recently found to undergo acetylation at K82 and K125, two lysine residues conserved in most species, and these modifications are required for secretion of CyPA in response to cell activation in vascular smooth muscle cells. Herein we addressed whether acetylation at these sites is also required for the release of CyPA from platelets based on the potential for local delivery of CyPA that may exacerbate cardiovascular disease events. Western blot analyses confirmed the presence of CyPA in human and mouse platelets. Thrombin stimulation resulted in CyPA release from platelets; however, no acetylation was observed—neither in cell lysates nor in supernatants of both untreated and activated platelets, nor after immunoprecipitation of CyPA from platelets. Shotgun proteomics detected two CyPA peptide precursors in the recombinant protein, acetylated at K28, but again, no acetylation was found in CyPA derived from resting or stimulated platelets. Our findings suggest that acetylation of CyPA is not a major protein modification in platelets and that CyPA acetylation is not required for its secretion from platelets. KW - Cyclophilin A KW - acetylation KW - platelets KW - CD147 KW - EMMPRIN Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284011 SN - 1422-0067 VL - 23 IS - 3 ER - TY - JOUR A1 - Rossow, Leonie A1 - Veitl, Simona A1 - Vorlová, Sandra A1 - Wax, Jacqueline K. A1 - Kuhn, Anja E. A1 - Maltzahn, Verena A1 - Upcin, Berin A1 - Karl, Franziska A1 - Hoffmann, Helene A1 - Gätzner, Sabine A1 - Kallius, Matthias A1 - Nandigama, Rajender A1 - Scheld, Daniela A1 - Irmak, Ster A1 - Herterich, Sabine A1 - Zernecke, Alma A1 - Ergün, Süleyman A1 - Henke, Erik T1 - LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy JF - Oncogene N2 - The potential of altering the tumor ECM to improve drug response remains fairly unexplored. To identify targets for modification of the ECM aiming to improve drug response and overcome resistance, we analyzed expression data sets from pre-treatment patient cohorts. Cross-evaluation identified a subset of chemoresistant tumors characterized by increased expression of collagens and collagen-stabilizing enzymes. We demonstrate that strong collagen expression and stabilization sets off a vicious circle of self-propagating hypoxia, malignant signaling, and aberrant angiogenesis that can be broken by an appropriate auxiliary intervention: Interfering with collagen stabilization by inhibition of lysyl oxidases significantly enhanced response to chemotherapy in various tumor models, even in metastatic disease. Inhibition of collagen stabilization by itself can reduce or enhance tumor growth depending on the tumor type. The mechanistical basis for this behavior is the dependence of the individual tumor on nutritional supply on one hand and on high tissue stiffness for FAK signaling on the other. KW - Cancer models KW - Cancer therapeutic resistance KW - Targeted therapies KW - Tumour angiogenesis Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227008 VL - 37 ER -